SCHEMBL345037

SCHEMBL345037

[CH2]c1cc(C(=O)NC)no1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
BAZ2B Q9UIF8 1/20 0.42
ROCK2 O75116 1/20 0.41
PIM1 P11309 1/20 0.41
GSK3B P49841 1/20 0.41
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
ALDH1A1 P00352 4/20 0.38
TP53 P04637 1/20 0.38
GLA P06280 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 7/20 0.37
PLK1 P53350 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
STAT3 P40763 1/20 0.35
IP6K1 Q92551 1/20 0.35
IP6K3 Q96PC2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL345038 0.78 MAPT (0.67) MAPTNPC1RAB9AALDH1A1TP53
SCHEMBL162398 0.78 MAPT (0.43) MAPTBAZ2BROCK2PIM1GSK3B
SCHEMBL18236195 0.76 ROCK2 (0.44) MAPTBAZ2BROCK2PIM1GSK3B
SCHEMBL4478564 0.76 MAPT (0.42) MAPTBAZ2BROCK2PIM1GSK3B
SCHEMBL13430874 0.74 SMN1; SMN2 (0.63) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL4901838 0.74
SCHEMBL14069154 0.73 THRB (0.56) MAPTNPC1RAB9AALDH1A1TP53
SCHEMBL26795644 0.73 ALDH1A1 (0.57) NPC1RAB9AALDH1A1HTTSMN1; SMN2
SCHEMBL344838 0.73 RAB9A (0.45) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2360702 0.73 USP2 (0.46) NPC1RAB9AALDH1A1TP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856735-B1 FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS UNIV NEW YORK (US) 2023-09-06 EP claimed
US-20210395222-A1 Fused Bicyclic Heterocycles as Therapeutic Agents NEW YORK UNIVERSITY 2021-12-23 US claimed
EP-3856735-A1 FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS New York University (US) 2021-08-04 EP claimed
WO-2020073031-A1 FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS NEW YORK UNIVERSITY (US) 2020-04-09 WO claimed
EP-2430006-B1 CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-26 EP claimed
EP-2430012-B1 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP claimed
EP-2393809-B1 DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-04-30 EP claimed
US-8697883-B2 Cyclopenta[C]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-04-15 US claimed
EP-2430012-A1 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-03-21 EP claimed
EP-2393809-A2 DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-12-14 EP claimed
WO-2010130945-A1 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-11-18 WO claimed
WO-2010089510-A2 DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-08-12 WO claimed
EP-3856735-B1 FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS UNIV NEW YORK (US) 2023-09-06 EP disclosed
US-20210395222-A1 Fused Bicyclic Heterocycles as Therapeutic Agents NEW YORK UNIVERSITY 2021-12-23 US disclosed
EP-3856735-A1 FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS New York University (US) 2021-08-04 EP disclosed
WO-2020073031-A1 FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS NEW YORK UNIVERSITY (US) 2020-04-09 WO disclosed
WO-2010130943-A1 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-11-18 WO disclosed
WO-2010130944-A1 CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-11-18 WO disclosed
WO-2010089510-A2 DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-08-12 WO disclosed
WO-2010055267-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395222-A1 Fused Bicyclic Heterocycles as Therapeutic Agents NAMPT, NQO1, NAPRT MAPT 785/4885BAZ2B 422/4885ROCK2 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.